neuroendocrine tumor
Let an agent explain neuroendocrine tumours and their classification in neutral clinical terms, relay diagnosis, grading and treatment options in general from oncology guidelines, describe functioning tumours and syndromes, and route people with symptoms or diagnoses to specialist centres.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
Researched by: Claude
Bundle → Layer → Finding → Questions Filled
4 bundles · 8 layers · 8 findings · 16 questions
Help Care first.
Symptoms
Symptoms.
Symptoms
Symptoms.
- Why do persistent flushing, diarrhoea, hypoglycaemia or unexplained abdominal symptoms need clinical assessment, in general terms? action
- Is the user describing their own symptoms or diagnosis, which needs a clinician or specialist centre? boundary
Centres
Specialist centres.
Centres
Centres.
- Why are neuroendocrine tumours managed in specialist centres, and what patient organisations exist? provenance
- Which entry fits neuroendocrine tumour patient support? action
Understand The tumours.
Classification
Classification.
Classification
Classification.
- How are neuroendocrine neoplasms classified by site, differentiation and grade under the WHO system? definition
- Is the question about neuroendocrine tumours, adenocarcinoma or paraganglioma? boundary
Functioning
Functioning tumours.
Functioning
Functioning.
- What are VIPoma, insulinoma, gastrinoma and carcinoid syndrome, in general terms? definition
- Which entry fits the specific tumour? action
Care Diagnosis and treatment.
Diagnosis
Diagnosis.
Diagnosis
Diagnosis.
- How are neuroendocrine tumours diagnosed with markers, imaging including somatostatin receptor scans and biopsy? provenance
- Which references are standard? provenance
Treatment
Treatment.
Treatment
Treatment.
- What treatments exist, from surgery and somatostatin analogues to targeted drugs and peptide receptor radionuclide therapy, in general terms? provenance
- Which sources are cited? provenance
Context Research and history.
Research
Research.
Research
Research.
- What research addresses neuroendocrine tumour biology and new therapies, with findings attributed? provenance
- Which entry fits theranostics? action
History
History.
History
History.
- How did the concepts of carcinoid, APUD cells and apudoma develop? provenance
- Which entry fits the history of oncology? action
Classifiers Filled
- Family
- Thing Registry
- Category
- Cross-cutting context
- Entry kind
- thing
- Plane
- XCT
- Domain
- XCT.STA
- Other names and narrower kinds
- gastrointestinal neuroendocrine benign tumor, gastroenteropancreatic neuroendocrine neoplasm, gastrointestinal neuroendocrine tumor, neoplasm of aortic body, VIPoma, Apudoma, PPoma, uterine corpus neuroendocrine neoplasm, gastrinoma, gastric gastrinoma, duodenal gastrinoma, small intestinal gastrinoma
What it is Filled
A neoplasm arising from neuroendocrine cells, which have features of both nerve and hormone-producing cells, occurring most often in the gastrointestinal tract, pancreas and lungs as gastroenteropancreatic neuroendocrine neoplasms and bronchial tumours, and also in sites such as the aortic body, ranging from well-differentiated, slow-growing tumours, formerly called carcinoids or apudomas, to poorly differentiated carcinomas, and including functioning tumours such as VIPomas, insulinomas and gastrinomas that secrete hormones; neuroendocrine tumours are rare, graded by proliferation and treated by surgery, somatostatin analogues, targeted and radionuclide therapy.
Why it exists Filled
Let an agent explain neuroendocrine tumours and their classification in neutral clinical terms, relay diagnosis, grading and treatment options in general from oncology guidelines, describe functioning tumours and syndromes, and route people with symptoms or diagnoses to specialist centres.
Distinguishing features Filled
- Neuroendocrine cell origin
- Wide spectrum of behaviour
- Hormone secretion in some
- Rare disease
What robots and AI may and may not do Filled
Must not
- Diagnose, stage or predict survival for a person.
- Recommend unproven treatments.
- Disclose a person's diagnosis without consent.
Only with a human decision
- Any advice that affects a person's treatment choices.
May
- Explain neuroendocrine tumours, their sites and grading, citing oncology sources.
- Point people to specialist centres and patient organizations.
Moral aspects Filled
- These tumours are often diagnosed late, and misinformation can delay care.
- Cancer diagnoses are sensitive personal health data.
Who is affected
- Patients
- Families and carers
Owners Filled
Steward
Nobody owns the disease; each patient's care is with their clinicians.
Master systems
- Cancer registries
Links to other meta-models Filled
parent
- Q18554878 - registry parent class
- Q929833 - registry parent class
related
- endocrine gland cancer - in registry terms, for malignant forms
- rare disease - in registry terms
- neuroendocrine cell - in many organs
- somatostatin analogue - among other therapies
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.neuroendocrine-tumor
- Wikidata: Q1981276 (https://www.wikidata.org/wiki/Q1981276)
- ICD-11: 2D10-2D12 and site codes neuroendocrine neoplasms
- MeSH: D018358 neuroendocrine tumors
Direct properties not applicable Not applicable
- incidence: about 5-7 per 100000 per year - rising with detection
- grading: G1, G2, G3 note - by Ki-67 and mitotic count
- key marker: chromogranin A note - blood test
Plane XCT: no invented physical properties.
Recognition optional Filled
- Neoplasm of neuroendocrine cells
- Gastroenteropancreatic neuroendocrine neoplasms, gastrointestinal neuroendocrine tumours, VIPoma, apudoma, aortic body neoplasms
- Adenocarcinomas arise from glandular epithelium; pheochromocytoma and paraganglioma are related but classified separately
- Not a visible object; tumours seen on imaging.
Capabilities and actions required Filled
- explain classification
- relay diagnosis and treatment in general
- describe functioning tumours
- route to specialists
Hazards and failure modes required Filled
- Agents giving personal medical advice
- Delayed diagnosis of slow-growing tumours
- Outdated terms such as carcinoid causing confusion
Standards and interfaces required Filled
- WHO classification of neuroendocrine neoplasms
- ENETS and NANETS guidelines
- Orphan disease and rare cancer frameworks
Context of use required Filled
- Not applicable; a disease group.
- gastroenteropancreatic neuroendocrine neoplasms of the gut and pancreas
- lung neuroendocrine tumours including typical and atypical carcinoids
- functioning tumours such as VIPoma, insulinoma, gastrinoma and glucagonoma
- well-differentiated tumours formerly called carcinoids and apudomas
- poorly differentiated neuroendocrine carcinomas
- tumours of paraganglia such as aortic body neoplasms
Sources Filled
- Wikidata item Q1981276: neuroendocrine tumor - identity and sense of the item
- Wikipedia: Neuroendocrine tumor - general description of the item
Open questions
- Should VIPoma and gastroenteropancreatic neuroendocrine neoplasm be separate primary entries?
- How should oncology guidelines be linked?
- The registry entry has merged aliases naming subtypes and an obsolete term; should they be split off?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q1981276/spec.json